Form 4: KORU COO Receives Significant Equity Awards

KORU Medical Systems' Chief Operating Officer, Christopher Pazdan, was granted substantial equity awards, including restricted stock units and stock options, as part of the company's 2025 Long-Term Incentive Program.

Summary

• Christopher Pazdan, Chief Operating Officer of KORU Medical Systems, Inc. (KRMD), received equity awards on May 12, 2025.
• Awards include 21,308 time-based Restricted Stock Units (RSUs), which vest one-fourth annually starting May 12, 2026, over four years.
• An additional 21,308 performance-based RSUs were granted, vesting contingent on achieving specific performance conditions by December 31, 2027, with potential payout ranging from 0% to 150% of the target amount, multiplied by 0.5 to 1.5 times the earned shares.
• 36,077 options to buy Common Stock were also awarded, with an exercise price of $3.21 per share.
• These options vest one-fourth annually starting May 12, 2026, over four years, and expire on May 12, 2035.
• All awards were made under the Company's 2024 Omnibus Equity Incentive Plan as part of the 2025 Long-Term Incentive Program.

Sentiment

Score: 7

Explanation: The filing indicates standard executive compensation through equity awards, which is generally positive as it aligns management incentives with shareholder interests. It does not contain negative financial news or significant operational issues.

Positives

• The equity awards align the Chief Operating Officer's interests with those of shareholders, incentivizing long-term performance and value creation.
• The awards are part of a structured Long-Term Incentive Program, indicating a commitment to executive retention and performance-based compensation.

Risks

• The performance-based restricted stock units carry a risk that the Reporting Person may earn 0% of the reported amount if performance conditions are not met by December 31, 2027.
• The value of the stock options is dependent on the future stock price exceeding the exercise price of $3.21, posing a risk if the stock underperforms.

Future Outlook

The equity awards are designed to incentivize the Chief Operating Officer's future performance, with vesting tied to both time-based schedules and the achievement of specific company performance conditions through December 31, 2027. This indicates a focus on long-term strategic goals and operational execution.

Management Comments

• The reported securities represent awards made pursuant to the Company's 2024 Omnibus Equity Incentive Plan in connection with the Company's 2025 Long-Term Incentive Program.

Industry Context

The granting of equity incentives to key executives is a standard practice across the medical device and broader healthcare industry. This compensation structure is commonly used to align executive interests with shareholder value creation and to retain top talent in a competitive market.

Comparison to Industry Standards

• The use of a combination of time-based and performance-based Restricted Stock Units (RSUs) along with stock options is a common and well-regarded compensation strategy in the industry, similar to practices at companies like Medtronic (MDT) or Boston Scientific (BSX) for their executive incentive programs.
• The multi-year vesting schedules (four years for time-based awards) are consistent with industry benchmarks aimed at fostering long-term commitment and discouraging short-term decision-making.
• The inclusion of performance conditions for a portion of the RSUs reflects a growing trend in corporate governance to tie executive pay directly to measurable company achievements, a practice seen in many leading healthcare technology firms.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity awards are designed to align the Chief Operating Officer's long-term interests with shareholder value creation, potentially leading to improved company performance.
• Employees: While specific to one executive, such incentive programs can signal a commitment to performance-based compensation, potentially influencing broader employee incentive structures.

Next Steps

• Vesting of time-based Restricted Stock Units and stock options will commence on May 12, 2026, and continue annually thereafter.
• Performance conditions for the performance-based Restricted Stock Units will be assessed as of December 31, 2027.

Key Dates

Keywords

KORU Medical Systems, KRMD, SEC Form 4, Insider Transaction, Equity Award, Restricted Stock Units, Stock Options, Executive Compensation, Long-Term Incentive Program, Corporate Governance